Atara Biotherapeutics Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application $(BLA.SI)$ for their innovative therapy, tabelecleucel (tab-cel®), with a Priority Review status. This application pertains to the use of tab-cel as a monotherapy for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) in both adult and pediatric patients who have undergone at least one prior therapy. Notably, there are currently no FDA-approved therapies available for this condition. The Priority Review includes a Class 2 Resubmission Prescription Drug User Fee Act (PDUFA) target action date set for January 10, 2026. This development marks a significant step towards introducing this first-of-its-kind treatment to patients in the U.S.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。